GAMMA Investing LLC lifted its position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) by 3,507.4% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,427 shares of the health services provider's stock after acquiring an additional 3,332 shares during the period. GAMMA Investing LLC's holdings in Amedisys were worth $317,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also made changes to their positions in the company. Trexquant Investment LP raised its position in shares of Amedisys by 1,317.8% during the 4th quarter. Trexquant Investment LP now owns 87,719 shares of the health services provider's stock valued at $7,964,000 after acquiring an additional 81,532 shares in the last quarter. Schonfeld Strategic Advisors LLC grew its stake in Amedisys by 17.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 4,500 shares of the health services provider's stock worth $409,000 after buying an additional 671 shares during the last quarter. Deutsche Bank AG grew its stake in Amedisys by 22.7% during the 4th quarter. Deutsche Bank AG now owns 2,524 shares of the health services provider's stock worth $229,000 after buying an additional 467 shares during the last quarter. Empowered Funds LLC bought a new position in Amedisys during the 4th quarter worth $318,000. Finally, KLP Kapitalforvaltning AS bought a new position in Amedisys during the 4th quarter worth $590,000. 94.36% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
AMED has been the subject of a number of recent research reports. Royal Bank Of Canada restated an "outperform" rating and set a $100.00 price objective on shares of Amedisys in a research note on Wednesday, April 16th. Wall Street Zen downgraded Amedisys from a "strong-buy" rating to a "buy" rating in a research note on Saturday, May 24th. Finally, Stephens restated an "equal weight" rating and set a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus price target of $100.75.
Get Our Latest Report on AMED
Amedisys Stock Performance
Shares of NASDAQ:AMED traded down $0.43 on Friday, hitting $97.46. The company's stock had a trading volume of 635,871 shares, compared to its average volume of 420,106. Amedisys, Inc. has a 12 month low of $82.15 and a 12 month high of $98.95. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of 35.96, a price-to-earnings-growth ratio of 1.32 and a beta of 0.94. The stock's 50-day moving average is $94.66 and its two-hundred day moving average is $92.22. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.29 and a current ratio of 1.29.
Amedisys (NASDAQ:AMED - Get Free Report) last released its quarterly earnings results on Wednesday, April 23rd. The health services provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.13 by $0.12. Amedisys had a return on equity of 12.52% and a net margin of 3.79%. The company had revenue of $594.78 million during the quarter, compared to analysts' expectations of $597.43 million. During the same quarter in the prior year, the business posted $1.03 earnings per share. The company's revenue for the quarter was up 4.1% compared to the same quarter last year. On average, equities research analysts forecast that Amedisys, Inc. will post 4.4 EPS for the current year.
About Amedisys
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
